@article{01KFG3SET3G7T9GQ8T03HREXJ7,
  abstract     = {{Background and aims Based on data from the EUROASPIRE IV survey, we aimed at assessing the possible residual risk tracked by serum apolipoprotein B in coronary patients with elevated serum triglycerides. Methods All samples from the total EUROASPIRE IV survey (n = 7998) with low serum total cholesterol (<4.5 mmol/L) and high serum triglycerides (>= 1.7 mmol/L) were used to analyse apolipoprotein A-I (apoA-I) and apolipoprotein B (apoB) concentrations (n = 938). We selected a similar number of participants (n = 938) with low total cholesterol and with low triglycerides (<1.0 mmol/L). In addition, phospholipid transfer protein (PLTP) and cholesteryl ester transfer protein (CETP) as well as paraoxonase-1 (PON-1), angiopoietin-like (ANGPTL)-3 and ANGPTL-8 were analysed in randomly selected participants. Results Despite the lower low-density lipoprotein cholesterol (LDL-C) concentration in the patients with TG >= 1.7 mmol/L (1.89 +/- 0.44 mmol/L) than those with TG < 1.0 mmol/L (1.99 +/- 0.43 mmol/L), p < 0.0001), serum total cholesterol, apoB, and HbA1c were all significantly (p < 0.0001) higher in patients with TG >= 1.7 mmol/L. In addition, high-density lipoprotein cholesterol (HDL-C), apoA-I, and CETP activity were significantly lower (p < 0.001) in these patients. The prevalence of obesity and diabetes was higher in the participants with TG >= 1.7 mmol/L than in those with TG < 1.0 mmol/L (52.6 % vs 21.9 % and 41.3 % vs. 20.0 %). Conclusions Statin treatment is mainly decreasing serum LDL-C concentration, but apoB measurements with excess serum triglycerides carried by apoB-containing lipoproteins could provide more specific information about the risk assessment of cardiovascular disease in atherogenic dyslipidemia.}},
  articleno    = {{120653}},
  author       = {{Leiviskä, Jaana and Sundvall, Jouko and Jauhiainen, Matti and Kotseva, Kornelia and Tuomilehto, Jaakko and De Backer, Gui and Tokgözoğlu, Lâle and Reiner, Zeljko and De Bacquer, Dirk}},
  issn         = {{0009-8981}},
  journal      = {{CLINICA CHIMICA ACTA}},
  keywords     = {{Triglycerides,Apolipoprotein B,LDL-C,Cardiovascular disease,HEART-DISEASE,NONFASTING TRIGLYCERIDES,REMNANT CHOLESTEROL,MANAGEMENT,ANGPTL3,LDL,DYSLIPIDEMIA,ASSOCIATION,PREVENTION,STILL}},
  language     = {{eng}},
  pages        = {{6}},
  title        = {{Residual cardiovascular risk is tracked by apolipoprotein B in coronary patients with elevated serum triglyceride levels : the ESC EORP EUROASPIRE IV survey}},
  url          = {{http://doi.org/10.1016/j.cca.2025.120653}},
  volume       = {{579}},
  year         = {{2026}},
}

Altmetric

View in Altmetric

Web of Science

Times cited: